Cara Therapeutics Inc said its arthritis drug met the main goal of reducing pain in patients in the first mid-stage study. The oral drug, CR845, was being evaluated in patients […]
FDA approves Baxalta’s treatment for common bleeding disorder
Approvals, Biotech, Bleeding, Bleeding Disorders, Blood Clots, Blood Clots, FDA, FDA/Regulatory, gegetic, Genetic Engineering, Genetics, Health, Hemophilia, Hemophilia, Immune Systems, Joints, Muscles, Oncology, Orphan Diseases, Orphan Drugs, Proteins, Rare Diseases, Shares, Shares, Willebrand DiseaseThe U.S. Food and Drug Administration on Tuesday approved Baxalta Inc’s Vonvendi, making it the first engineered protein-based treatment for the world’s most common inherited bleeding disorder. Vonvendi treats Willebrand […]
